Table 2 In vitro antifungal susceptibility of Candida species isolated from surgical patients with candidemia
Species | Antifungal agent | MIC (μg/ml) | No. (%) of isolates by new CBPsa | ||||
|---|---|---|---|---|---|---|---|
(n = 172) |  | Ranges | MIC50 | MIC90 | S | SDD / I | R |
C. albicans (n = 58) | Fluconazole | ≤0.5–16 | ≤1 | 4 | 50 (86.2%) | 6 (10.3%) | 2 (3.4%) |
Voriconazole | ≤0.03- ≤ 4 | 0.06 | ≤1 | 49 (84.5%) | 3 (5.2%) | 6 (10.3%) | |
Itraconazole | 0.062–1 | ≤0.125 | 0.25 | NA | NA | NA | |
Amphotericin B | ≤0.25–1 | ≤0.5 | 0.5 | 58 (100%) | 0 | 0 | |
C. parapsilosis (n = 74) | Fluconazole | ≤0.5–8 | ≤1 | ≤4 | 65 (87.8%) | 8 (10.8%) | 1 (1.4%) |
Voriconazole | ≤0.03–0.25 | ≤0.06 | 0.125 | 72 (97.3%) | 2 (2.7%) | 0 | |
Itraconazole | ≤0.062–0.25 | ≤0.125 | 0.125 | 72 (97.3%) | 0 | 2 (2.7%) | |
Amphotericin B | ≤0.25–1 | ≤0.5 | 0.5 | 74 (100%) | 0 | 0 | |
C. glabrata (n = 19) | Fluconazole | ≤1–16 | 4 | 16 | 0 | 19 (100%) | 0 |
Voriconazole | ≤0.06–0.5 | 0.125 | 0.25 | NA | NA | NA | |
Itraconazole | ≤0.125–1 | 0.25 | 1 | NA | NA | NA | |
Amphotericin B | ≤0.25–1 | ≤0.5 | 0.5 | 19 (100%) | 0 | 0 | |
C. tropicalis (n = 14) | Fluconazole | ≤1–32 | 1 | 16 | 11 (78.6%) | 1 (7.1%) | 2 (14.3%) |
Voriconazole | ≤0.06–4 | 0.06 | 0.5 | 12 (85.7%) | 1 (7.1%) | 1 (7.1%) | |
Itraconazole | ≤0.125–8 | 0.125 | 1 | 10 (71.4%) | 0 | 4 (28.6%) | |
Amphotericin B | ≤0.25–0.5 | ≤0.5 | 0.5 | 14 (100%) | 0 | 0 | |
C. kruseib (n = 1) | Fluconazole | 64 |  |  | 0 | 0 | 1 (100%) |
Voriconazole | 0.5 | Â | Â | 1 (100%) | 0 | 0 | |
Itraconazole | 1 | Â | Â | NA | NA | NA | |
Amphotericin B | 1 | Â | Â | 1 (100%) | 0 | 0 | |
Others (n = 6) | Fluconazole | ≤1–16 | ≤2 | 16 | NA | NA | NA |
Voriconazole | ≤0.06–2 | ≤0.06 | 2 | NA | NA | NA | |
Itraconazole | ≤0.125–1 | 0.125 | 1 | NA | NA | NA | |
Amphotericin B | ≤0.5–0.5 | ≤0.5 | 0.5 | NA | NA | NA | |